Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC12A2 | P55011 | 1/20 | 0.52 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1691225 | 1.00 | SLC12A2 (0.52) | SLC12A2SLC12A5GAAPOLBALOX12 | |
| SCHEMBL1691084 | 1.00 | SLC12A2 (0.52) | SLC12A2SLC12A5GAAPOLBALOX12 | |
| SCHEMBL2306082 | 0.96 | SLC12A2 (0.56) | SLC12A2SLC12A5GAAPOLBALOX12 | |
| SCHEMBL283634 | 0.96 | SLC12A2 (0.56) | SLC12A2SLC12A5GAAPOLBALOX12 | |
| SCHEMBL283635 | 0.96 | SLC12A2 (0.56) | SLC12A2SLC12A5GAAPOLBALOX12 | |
| SCHEMBL19285120 | 0.91 | SLC12A2 (0.47) | SLC12A2SLC12A5GAAPOLBALOX12 | |
| SCHEMBL19285370 | 0.91 | SLC12A2 (0.47) | SLC12A2SLC12A5GAAPOLBALOX12 | |
| SCHEMBL283511 | 0.91 | SLC12A2 (0.47) | SLC12A2SLC12A5GAAPOLBALOX12 | |
| SCHEMBL14239450 | 0.86 | SLC12A2 (0.50) | SLC12A2SLC12A5GAAPOLBALOX12 | |
| SCHEMBL3609709 | 0.86 | ALDH1A1 (0.42) | POLBMEN1KMT2ASMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | claimed |
| US-20230150986-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2023-05-18 | — | — | US | claimed |
| US-20230122344-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2023-04-20 | — | — | US | claimed |
| EP-4139303-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2023-03-01 | — | — | EP | claimed |
| WO-2021216951-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2021-10-28 | — | — | WO | claimed |
| WO-2021119254-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2021-06-17 | — | — | WO | claimed |
| WO-2021119265-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2021-06-17 | — | — | WO | claimed |
| US-12617777-B2 | GPR84 antagonists and uses thereof | Liminal Biosciences Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2025-02-27 | — | — | US | disclosed |
| WO-2024218296-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| EP-4422750-A1 | LRRK2 INHIBITORS | H. Lundbeck A/S (DK) | 2024-09-04 | — | — | EP | disclosed |
| EP-3604305-B1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-20080194549-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1863477-A1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | Novartis AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | disclosed |
| EP-0785933-A1 | INDOLE DERIVATIVES AS 5HT1-LIKE AGONISTS | Pfizer Limited (GB) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011195-A1 | INDOLE DERIVATIVES AS 5HT1-LIKE AGONISTS | PFIZER LIMITED (GB) | 1996-04-18 | — | — | WO | disclosed |
| US-4606753-A | PLANT GROWTH REGULATORS | SHELL OIL COMPANY (US) | 1986-08-19 | — | — | US | disclosed |
| US-4588821-A | 2-oxabicyclo[2.2.1]heptan-6-ol ether herbicides | SHELL OIL COMPANY (US) | 1986-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L2, BCL2L1 | SLC12A2 436/4885SLC12A5 732/4885GAA 4803/4885 |
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | SLC12A2 3490/4885SLC12A5 3461/4885GAA 3428/4885 |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L1, BCL2L2 | SLC12A2 1814/4885SLC12A5 1957/4885GAA 4169/4885 |
| US-12617777-B2 | GPR84 antagonists and uses thereof | GPR84, GPR88, GPR3 | SLC12A2 972/4885SLC12A5 1175/4885GAA 4713/4885 |
| US-20080194549-A1 | Organic Compounds | REN, ACE, OTC | SLC12A2 3030/4885SLC12A5 2444/4885GAA 118/4885 |
| US-20230122344-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | SLC12A2 4238/4885SLC12A5 4008/4885GAA 2596/4885 |
| US-20230150986-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | SLC12A2 3894/4885SLC12A5 3708/4885GAA 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.